| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | |
|---|---|---|---|---|---|---|
Cash flows from operating activities: | ||||||
Net loss | ||||||
-30,774 | -13,335 | -15,385 | - | - | - | |
Net loss | ||||||
- | - | - | -12,065 | -15,908 | -13,237 | |
Loss from discontinued operations | ||||||
- | -1,494 | -3,593 | -5,327 | -6,168 | - | |
Loss from continuing operations | ||||||
-30,774 | -11,841 | -11,792 | -6,737 | -9,740 | - | |
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||
Depreciation and amortization | ||||||
1,958 | 1,963 | 1,611 | 18 | 10 | 28 | |
Noncash lease expense | ||||||
386 | - | - | - | - | - | |
Stock-based compensation expense | ||||||
825 | 1,263 | 880 | 739 | 730 | - | |
Income tax benefit | ||||||
- | - | -1,651 | 0 | - | - | |
Board fees paid with common stock | ||||||
- | - | 278 | 24 | 0 | - | |
Stock-based compensation expense | ||||||
- | - | - | - | - | 345 | |
Change in fair value of stock warrants | ||||||
6,964 | -522 | 685 | -1,667 | 515 | - | |
Change in fair value of contingent consideration | ||||||
289 | 567 | 2,492 | - | - | - | |
Non-cash interest expense relating to line of credit | ||||||
- | - | - | - | - | 1 | |
Change in fair value of contingent consideration | ||||||
- | - | - | 0 | - | - | |
Loss on disposition of property & equipment | ||||||
- | - | - | -0 | 0 | -7 | |
Non-cash interest expense relating to convertible promissory notes & amortization of discount on notes | ||||||
- | - | - | - | - | 4,128 | |
Inducement charge for Series C warrants | ||||||
- | - | - | 0 | 3,049 | 0 | |
Change in fair value of common stock warrants | ||||||
- | - | - | - | - | 3,941 | |
Non-cash expense of issuing shares to Aspire Capital | ||||||
- | - | 602 | 0 | 183 | 0 | |
Gain on deconsolidation of former subsidiary | ||||||
- | 1,994 | - | - | - | - | |
Operating loss on minority interest investment | ||||||
-478 | -160 | - | - | - | - | |
Change in operating assets and liabilities: | ||||||
Accounts receivable | ||||||
- | - | - | - | - | -149 | |
Inventory | ||||||
- | - | - | - | - | 109 | |
Other receivables | ||||||
- | - | - | - | - | 0 | |
Prepaid expenses, other current assets and other assets | ||||||
-10 | 60 | 97 | -87 | -77 | 167 | |
Due from related party | ||||||
-64 | 64 | - | - | - | - | |
Other long-term assets | ||||||
- | - | - | -49 | 76 | 0 | |
Accounts payable | ||||||
1,061 | 249 | 191 | -76 | -435 | 353 | |
Accrued compensation | ||||||
9 | -103 | - | - | - | - | |
Accrued clinical trial site costs | ||||||
1,679 | 321 | - | - | - | - | |
Operating lease liabilities | ||||||
-360 | - | - | - | - | - | |
Other liabilities | ||||||
36 | -261 | - | - | - | - | |
Accrued compensation and other liabilities | ||||||
- | - | -78 | 534 | 115 | - | |
Accrued compensation and other current liabilities | ||||||
- | - | - | - | - | 72 | |
Other long-term liabilities | ||||||
- | - | -40 | 40 | 0 | - | |
Net cash used in continuing operating activities | ||||||
-17,375 | -10,322 | -6,919 | -7,260 | -5,568 | - | |
Net cash used in discontinued operating activities | ||||||
- | -1,361 | -3,031 | -6,237 | -4,730 | - | |
Net cash used in operating activities | ||||||
-17,375 | -11,683 | -9,950 | -13,497 | -10,299 | -4,484 | |
Cash flows from investing activities: | ||||||
Costs of Essentialis acquisition paid | ||||||
- | - | 573 | - | - | - | |
Cash paid for purchase of assets of NeoForce Group, Inc. | ||||||
- | - | - | - | - | 0 | |
Acquisition of BDDI asset (patent) | ||||||
- | - | - | - | - | 0 | |
Increase in restricted cash | ||||||
- | - | - | - | 15 | - | |
Costs of Essentialis acquisition paid | ||||||
- | - | - | 0 | - | - | |
Increase in restricted cash | ||||||
- | - | - | - | - | 0 | |
Security deposit on sublease | ||||||
- | - | 13 | 0 | - | - | |
Purchases of property and equipment | ||||||
21 | 8 | 2 | 14 | 44 | 30 | |
Security deposit on sublease | ||||||
59 | - | - | - | - | - | |
Security deposit received from expired lease | ||||||
108 | - | - | - | - | - | |
Proceeds from sale of minority interest investment in former subsidiary | ||||||
500 | - | - | - | - | - | |
Net cash provided by (used in) continuing investing activities | ||||||
528 | -8 | -562 | -14 | -59 | - | |
Net cash used in discontinued investing activities | ||||||
- | -172 | 716 | -23 | -1,261 | - | |
Net cash used in investing activities | ||||||
528 | -180 | 154 | -38 | -1,320 | -30 | |
Cash flows from financing activities: | ||||||
Proceeds from sale of common stock and common stock warrants, net of costs | ||||||
14,483 | 16,302 | - | - | - | - | |
Principal paid on finance lease liabilities | ||||||
2 | - | - | - | - | - | |
Cash paid for the cost issuance of common stock and common stock warrants | ||||||
- | - | - | 0 | - | - | |
Proceeds from exercise of common stock options | ||||||
- | - | - | 70 | 293 | 0 | |
Proceeds from issuance of common stock | ||||||
- | - | 10,000 | 0 | 1,434 | 0 | |
Proceeds from sale of common stock and common stock warrants | ||||||
- | - | 15,008 | 0 | - | - | |
Cash paid for the issuance of common stock and common stock warrants | ||||||
- | - | 1,063 | - | - | - | |
Repayment of credit line | ||||||
- | - | - | - | 101 | 0 | |
Proceeds from issuance of preferred stock warrants | ||||||
- | - | - | - | - | 1 | |
Proceeds from issuance of convertible notes payable | ||||||
- | - | - | - | - | 2,490 | |
Proceeds from line of credit | ||||||
- | - | - | - | - | 100 | |
Proceeds from Initial Public Offering | ||||||
- | - | - | - | - | 10,727 | |
Cash paid for the issuance cost of common stock and common stock warrants | ||||||
- | - | - | - | 575 | 2,117 | |
Net cash provided by continuing financing activities | ||||||
14,481 | 16,302 | 23,945 | 10,768 | 9,157 | - | |
Net cash provided by discontinued financing activities | ||||||
- | 1,525 | 225 | 0 | 0 | - | |
Net cash used in financing activities | ||||||
14,481 | 17,827 | 24,170 | 10,768 | 9,157 | 11,202 | |
Net increase (decrease) in cash and cash equivalents | ||||||
- | - | - | -2,768 | -2,462 | 6,687 | |
Net decrease in cash and cash equivalents | ||||||
-2,366 | 5,964 | 14,374 | - | - | - | |
Cash paid for income taxes | ||||||
- | - | - | 0 | - | - | |
Supplemental disclosures of non-cash investing and financing information | ||||||
Series A preferred convertible stock transaction costs included in Accounts Payable | ||||||
- | - | - | - | - | 0 | |
Conversion of preferred to common stock | ||||||
- | - | - | - | - | 23,808 | |
Patent costs included in Accrued liabilities | ||||||
- | - | - | - | - | 0 | |
Issuance of common stock in Essentialis acquisition | ||||||
- | - | 17,246 | 0 | 112 | 0 | |
Contingent consideration of Essentialis acquisition | ||||||
- | - | 2,590 | 0 | - | - | |
Accrued liability for cost of issuing common stock | ||||||
- | 52 | - | - | - | - | |
Warrants issued in connection with sale of common stock | ||||||
- | 582 | 4,187 | 0 | - | - | |
Costs of issuing common stock and common stock warrants recorded in accounts payable | ||||||
- | - | - | 0 | - | - | |
Preferred convertible stock transaction costs included in Accounts Payable | ||||||
- | - | - | 52 | - | - | |
Fixed asset purchases in accounts payable | ||||||
- | - | - | 11 | 0 | - | |
Contingent consideration of Essentialis acquisition | ||||||
- | - | 2,590 | 0 | - | - | |
Cashless exercise of 2010 and 2012 warrants | ||||||
- | - | - | - | 0 | 0 | |
Contribution of Series B warrants | ||||||
- | - | - | - | 3 | - | |
Initial public offering costs accrued and included in accounts payable | ||||||
- | - | - | - | - | 575 | |
Beneficial conversion feature related to the warrants to purchase shares of convertible preferred stock in connection with convertible promissory notes | ||||||
- | - | - | - | - | 1,723 | |
Issuance of warrants for the purchase of convertible preferred stock in connection with notes payable | ||||||
- | - | - | - | - | 966 | |
Continuing Operations [Member] | ||||||
Net increase (decrease) in cash and cash equivalents | ||||||
-2,366 | 5,972 | 16,464 | - | - | - | |
Discontinued Operations [Member] | ||||||
Net increase (decrease) in cash and cash equivalents | ||||||
- | -8 | -2,090 | - | - | - | |